|
Viking Therapeutics, Inc. (VKTX) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Viking Therapeutics, Inc. (VKTX) Bundle
Optimize your time and improve precision with our (VKTX) DCF Calculator! Utilizing real data from Viking Therapeutics, Inc. and customizable assumptions, this tool empowers you to forecast, analyze, and evaluate (VKTX) like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -25.4 | -42.7 | -55.4 | -70.4 | -100.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .3 | .3 | .3 | .3 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -25.6 | -42.9 | -55.7 | -70.6 | -100.8 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 275.6 | 248.4 | 202.1 | 155.5 | 362.1 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 2.4 | 4.0 | 1.4 | 8.5 | 7.5 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -25.6 | -39.2 | -54.7 | -69.1 | -100.8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -22.9 | -37.4 | -56.9 | -61.7 | -101.8 | -7.5 | .0 | .0 | .0 | .0 |
| WACC, % | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -6.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -7 | |||||||||
| Net Debt | -54 | |||||||||
| Equity Value | 47 | |||||||||
| Diluted Shares Outstanding, MM | 94 | |||||||||
| Equity Value Per Share | 0.50 |
What You Will Get
- Real Viking Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Viking Therapeutics, Inc. (VKTX).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis needs.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Viking Therapeutics' fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections specific to Viking Therapeutics, Inc. (VKTX).
- Time-Saving and Accurate: Eliminate the hassle of building models from scratch while ensuring precision and flexibility.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Viking Therapeutics, Inc. (VKTX).
- WACC Calculator: Includes a pre-built Weighted Average Cost of Capital sheet with customizable inputs specific to VKTX.
- Adjustable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates relevant to Viking Therapeutics.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Viking Therapeutics, Inc. (VKTX).
- Interactive Dashboard and Charts: Visual outputs present key valuation metrics for straightforward analysis.
How It Works
- Download: Obtain the comprehensive Excel file featuring Viking Therapeutics, Inc. (VKTX) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time for accurate insights.
- Test Scenarios: Develop various projections and instantly compare different outcomes.
- Make Decisions: Leverage the valuation results to inform your investment strategy with Viking Therapeutics, Inc. (VKTX).
Why Choose This Calculator?
- User-Friendly Interface: Perfect for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your analytical needs.
- Real-Time Feedback: Observe immediate updates to Viking Therapeutics’ valuation as you tweak inputs.
- Preloaded Data: Comes with Viking Therapeutics’ actual financial metrics for swift evaluations.
- Relied Upon by Experts: Utilized by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Investors: Accurately estimate Viking Therapeutics, Inc.'s (VKTX) fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Viking Therapeutics, Inc. (VKTX).
- Consultants: Quickly customize the template for valuation reports tailored to clients focused on Viking Therapeutics, Inc. (VKTX).
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms like Viking Therapeutics, Inc. (VKTX).
- Educators: Implement it as a teaching resource to illustrate valuation methodologies relevant to the biotech sector, including Viking Therapeutics, Inc. (VKTX).
What the Template Contains
- Historical Data: Includes Viking Therapeutics’ past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Viking Therapeutics’ intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Viking Therapeutics’ financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.